Sign in

    Avantika Joshi • Mizuho Securities

    Avantika Joshi's questions to Immunocore Holdings PLC (IMCR) leadership

    Avantika Joshi's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Avantika Joshi from Mizuho Securities asked if Immunocore is still evaluating brenetafusp in tumors beyond melanoma, ovarian, and lung, and whether early-stage assets would utilize basket studies or focus on specific tumors.

    Answer

    CFO Brian Di Donato confirmed interest in other tumors like endometrial but stated the team's current focus is on the three main programs. Mohammed Dar, an executive, explained that for early-stage PRAME assets, learnings are being applied from the lead program, and the trials are designed to enroll patients across multiple tumor types where PRAME is expressed.

    Ask Fintool Equity Research AI

    Avantika Joshi's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Avantika Joshi from Mizuho Securities asked if Immunocore is exploring brenetafusp in tumors beyond the main three and whether the early-stage assets are being studied in basket trials or specific tumors.

    Answer

    Executive Brian Di Donato confirmed interest in other tumors like endometrial but said the team is focused on the three priority indications. Mohammed Dar, an executive, explained that learnings from the main PRAME program allow the newer trials to enroll multiple patient types where PRAME is expressed.

    Ask Fintool Equity Research AI